Mills Kenneth T. 4
4 · REGENXBIO Inc. · Filed May 14, 2025
Insider Transaction Report
Form 4
REGENXBIO Inc.RGNX
Mills Kenneth T.
Director
Transactions
- Sale
Common Stock
2025-05-12$7.91/sh−20,602$163,046→ 475,103 total - Exercise/Conversion
Common Stock
2025-05-12$3.76/sh+20,602$77,464→ 495,705 total - Exercise/Conversion
Stock Options (Right to Buy)
2025-05-12−20,602→ 0 totalExercise: $3.76Exp: 2025-05-19→ Common Stock (20,602 underlying)
Footnotes (3)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan.
- [F2]This transaction was executed in multiple trades at prices ranging from $7.66 to $8.04. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F3]The previously granted option, representing a right to purchase a total of 275,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2016, and the balance vested in equal monthly installments over the 36 months thereafter.